Quoin Pharmaceuticals (NASDAQ:QNRX) CFO Acquires $49,990.72 in Stock

Quoin Pharmaceuticals, Ltd. Sponsored ADR (NASDAQ:QNRX) CFO Sally Bridget Lawlor bought 10,244 shares of the stock in a transaction dated Monday, August 31st. The stock was acquired at an average price of $4.88 per share, with a total value of $49,990.72. Following the completion of the purchase, the chief financial officer owned 10,684 shares of the company’s stock, valued at $52,137.92. This represents a 2,328.18% increase in their position. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available through this link.

Quoin Pharmaceuticals Trading Up 4.7%

Shares of Quoin Pharmaceuticals stock traded up $0.29 during trading on Tuesday, reaching $6.51. The company’s stock had a trading volume of 274,471 shares, compared to its average volume of 1,602,162. The stock has a 50-day moving average price of $4.77 and a two-hundred day moving average price of $5.89. The stock has a market capitalization of $13.09 million, a P/E ratio of -0.26 and a beta of 1.50. Quoin Pharmaceuticals, Ltd. Sponsored ADR has a one year low of $3.25 and a one year high of $41.80.

Quoin Pharmaceuticals (NASDAQ:QNRX) last issued its quarterly earnings data on Friday, August 14th. The company reported ($1.90) EPS for the quarter, missing analysts’ consensus estimates of ($1.61) by ($0.29). As a group, sell-side analysts anticipate that Quoin Pharmaceuticals, Ltd. Sponsored ADR will post -7.38 EPS for the current fiscal year.

Hedge Funds Weigh In On Quoin Pharmaceuticals

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. Simplify Asset Management Inc. acquired a new stake in Quoin Pharmaceuticals during the 4th quarter worth $252,000. SummitTX Capital L.P. raised its position in shares of Quoin Pharmaceuticals by 54.8% during the 1st quarter. SummitTX Capital L.P. now owns 100,300 shares of the company’s stock valued at $662,000 after acquiring an additional 35,505 shares during the last quarter. ADAR1 Capital Management LLC acquired a new position in shares of Quoin Pharmaceuticals in the 4th quarter valued at $840,000. Boothbay Fund Management LLC acquired a new position in shares of Quoin Pharmaceuticals in the 4th quarter valued at $863,000. Finally, Millennium Management LLC bought a new position in shares of Quoin Pharmaceuticals in the 4th quarter worth $1,080,000. 8.63% of the stock is owned by institutional investors.

Analyst Ratings Changes

Several research firms have recently commented on QNRX. Weiss Ratings reissued a “sell (e+)” rating on shares of Quoin Pharmaceuticals in a research note on Monday, July 20th. ThinkEquity initiated coverage on shares of Quoin Pharmaceuticals in a research report on Monday, June 15th. They issued a “buy” rating for the company. One research analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the stock currently has a consensus rating of “Hold”.

About Quoin Pharmaceuticals

Quoin Pharmaceuticals, Ltd., a clinical stage specialty pharmaceutical company, focuses on the development and commercialization of therapeutic products for rare and orphan diseases. Its lead product is QRX003, a topical lotion to treat Netherton Syndrome (NS). The company is also developing QRX004 for the treatment of recessive dystrophic epidermolysis bullosa; QRX007 to treat NS; and QRX008 for the treatment of scleroderma. It has a research agreement with Queensland University of Technology; a license agreement with Skinvisible Inc; consulting agreements with Axella Research LLC; and a Master Service Agreement with Therapeutics Inc The company was founded in 2018 and is based in Ashburn, Virginia.